Pancreatic cancer therapies progress despite mixed investor response

It has been a good week for pancreatic cancer therapies in development, with readouts from Alligator and Candel suggesting two different mechanisms may improve survival.

The largest gainer on clinical data over the past seven days was Alligator Bioscience AB (SSE:ATORX), with shares rising 195% on Wednesday on news that first-line treatment incorporating anti-CD40 antibody mitazalimab tripled the 24-month survival rate in a metastatic pancreatic cancer study over chemotherapy alone. The move translates to a gain in market cap of 1.3B SEK ($120M), as any survival advantage in pancreatic cancer is notable...